Amylyx Pegasus

Have you been diagnosed with Mild Cognitive Impairment (MCI) or Alzheimer’s Disease (AD)? We are interested in testing if a combination therapy (AMX0035) can reduce neuroinflammation and neuronal death in patients with MCI or probable AD.Age: 55-89 and diagnosis of MCI or probable AD

 

Double-Blind study for 32 weeks

Reimbursement: Up to $300, free parking and lunch at each in-person visit

If you interested, please contact Lisa Quinn, PhD, NP at LWQuinn@mgh.harvard.edu  or 617-724-4076